Related Business Topics
Latest Headlines
Reuters - Nov. 11, 2009, 6:42 AM
Updated Analyses of Phase 1/2 Clinical Trial of KRX-0401 in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009 NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today ...
CNBC - Nov. 11, 2009, 5:47 AM
CNBC - Nov. 11, 2009, 5:47 AM
Reuters - Nov. 11, 2009, 5:44 AM
7:00am EST storyKeywords RTR_ArticleTitle 'AEterna Zentaris Reports Third Quarter 2009 Financial and Operating RTR_ArticleBlurb 'All amounts are in dollars QUEBEC CITY, Nov. 11 /PRwireFirstCall/ AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the ...
CNBC - Nov. 9, 2009, 2:32 PM
Forbes.com - Nov. 9, 2009, 2:24 PM
Nov 9 (Reuters) - Keryx Biopharmaceuticals Inc: * Announces third quarter 2009 financial results * Q3 earnings per share $0.01 * Q3 revenue ...
CNBC - Nov. 9, 2009, 1:53 PM
Forbes.com - Nov. 6, 2009, 6:57 AM
NEW YORK In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a ...
CNBC - Nov. 6, 2009, 6:00 AM
Forbes.com - Oct. 29, 2009, 6:35 AM
NEW YORK Mr. Bentsur's presentation will be webcast live on Wednesday, November 4th About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical ...
